Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial

<div>A 47-year-old female patient with refractory patches on the dorsal aspect of her left forearm: (a) before treatment; (b) six months’ follow-up after treatment by topical pimecrolimus 1% on the pointed lesion. No changes were observed.</div>

Dermatology Research and Practice

fig3

Figure 3

Figure 3: Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial 

Figure 3 | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial 